Theresa Lanham, DO
Endocrinology, Diabetes & Metabolism · Owensboro, KYNPI 1972037208
Payments from drug & device makers
Across 125 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$453
- Lilly USA, LLC$347
- Amgen$251
- Insulet Corporation$223
- Medtronic$186
- AstraZeneca$164
- plus $607 from 13 others
What the payments were for
- Food & beverage$2,231100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $453 |
| Lilly USA, LLC | 18 | $347 |
| Amgen | 15 | $251 |
| Insulet Corporation | 11 | $223 |
| Medtronic | 9 | $186 |
| AstraZeneca | 9 | $164 |
| Corcept Therapeutics | 6 | $101 |
| Bayer | 5 | $79 |
| Tandem Diabetes Care, Inc. | 3 | $65 |
| Kyowa Kirin, Inc. | 3 | $61 |
| Recordati_rare_diseases_inc. | 3 | $55 |
| Dexcom, Inc. | 2 | $42 |
| Novartis | 2 | $39 |
| Ascensia Diabetes Care US Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $35 |
| AbbVie | 2 | $33 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Radius Health, Inc. | 1 | $17 |
| Alvogen Inc | 1 | $17 |
How this compares
$2,231 in reported general payments places this provider in the 30th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 294 | $296,896 |
| MounjaroTirzepatide | 141 | $147,777 |
| TrulicityDulaglutide | 81 | $89,450 |
| JardianceEmpagliflozin | 114 | $87,109 |
| JanuviaSitagliptin Phosphate | 65 | $46,483 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $44,099 |
| RybelsusSemaglutide | 38 | $32,752 |
| FarxigaDapagliflozin Propanediol | 44 | $31,499 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $24,876 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $17,311 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $16,928 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $14,877 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 15 | $12,760 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $12,667 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $11,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $453 | $329,648332 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $347 | $238,686235 claims |
| Boehringer IngelheimJardiance | $35 | $87,109114 claims |
| AstraZenecaFarxiga | $164 | $31,49944 claims |
| AbbVieSynthroid | $33 | $4,01961 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Owensboro
- Betty VillafuerteOwensboro$32K
- Mary de CroosOwensboro$3K
- Harold BaysLouisville$12.9M
- Bradley EilermanFlorence$1.9M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Wael EidCovington$509K
- Lyle MyersLexington$434K
- Sathya KrishnasamyLouisville$263K
- Dennis KarounosLexington$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.